SITE005-0212

SITE005 (FRA) › SITE005-0212

SITE005-0212

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2026-05-04

enrolled

AEs

2

Serious

0

Dropout signal

–

Adverse events

2

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-02-10 (study day 91); relationship: not assessed

moderate assessed

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-01-04 (study day 54); relationship: NOT RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.